EXHIBIT
      31.1





CERTIFICATION
      PURSUANT TO RULE 13A-14 OR 15D-14 OF THE SECURITIES


EXCHANGE
      ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF


THE
      SARBANES-OXLEY ACT OF 2002





I,
      Henry
      Fong, certify that:





1.   I
      have reviewed this Quarterly Report on Form 10-Q of Inhibiton Therapeutics,
      Inc.
      (the "registrant);





2.   Based
      on my knowledge, this report does not contain any untrue statement of a material
      fact or omit to state a material fact necessary to make the statements made,
      in
      light of the circumstances under which such statements were made, not misleading
      with respect to the period covered by this report;





3.   Based
      on my knowledge, the financial statements, and other financial information
      included in this report, fairly present in all material respects the financial
      condition, results of operations and cash flows of the registrant as of, and
      for, the periods presented in this report;





4.   I
      am responsible for establishing and maintaining disclosure controls and
      procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the
      registrant and have:





(a)
      Designed such disclosure controls and procedures, or caused such disclosure
      controls and procedures to be designed under my supervision, to ensure that
      material information relating to the registrant, including its consolidated
      subsidiaries, is made known to me by others within those entities, particularly
      during the period in which this report is being prepared;





(b)
      [Paragraph omitted in accordance with SEC transition instructions contained
      in
      SEC Release 34-47986];





(c)
      Evaluated the effectiveness of the registrant's disclosure controls and
      procedures and presented in this report my conclusion about the effectiveness
      of
      the disclosure controls and procedures, as of the end of the period covered
      by
      this report based on such evaluation; and





(d)
      Disclosed in this report any change in the registrant's internal control over
      financial reporting that occurred during the registrant's most recent fiscal
      quarter that has materially affected, or is reasonably likely to materially
      affect, the registrant's internal control over financial reporting; and





5.   I
      have disclosed, based on my most recent evaluation of internal control over
      financial reporting, to the registrant's auditors and the audit committee of
      the
      registrant's board of directors (or persons performing the equivalent
      functions):





(a)
      All significant deficiencies and material weaknesses in the design or operation
      of internal control over financial reporting which are reasonably likely to
      adversely affect the registrant's ability to record, process, summarize and
      report financial information; and





(b)
      Any fraud, whether or not material, that involves management or other employees
      who have a significant role in the registrant's internal control over financial
      reporting.





Date:  June
                20, 2008
            /s/
                Henry FongHenry
                FongPrincipal
                Executive Officer and
              Principal
                Accounting Officer